EMCURE

Emcure Pharmaceuticals Share Price

₹1,372.90 -16.15 (-1.16%)

21 Dec, 2024 18:55

SIP TrendupStart SIP in EMCURE

Start SIP

Performance

  • Low
  • ₹1,345
  • High
  • ₹1,385
  • 52 Week Low
  • ₹1,225
  • 52 Week High
  • ₹1,580
  • Open Price₹1,378
  • Previous Close₹1,389
  • Volume73,365

Investment Returns

  • Over 1 Month + 5.14%
  • Over 3 Month -5.22%
  • Over 6 Month + 36.2%
  • Over 1 Year + 36.2%
SIP Lightning

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45.8
  • PEG Ratio
  • -
  • Market Cap Cr
  • 26,007
  • P/B Ratio
  • 8.3
  • Average True Range
  • 42.85
  • EPS
  • 30.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.37
  • RSI
  • 48.88
  • MFI
  • 47.47

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,372.90
-16.15 (-1.16%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹1,376.48
  • 50 Day
  • ₹1,383.37
  • 100 Day
  • ₹1,382.66
  • 200 Day
  • -

Resistance and Support

1367.63 Pivot Speed
  • R3 1,430.27
  • R2 1,407.63
  • R1 1,390.27
  • S1 1,350.27
  • S2 1,327.63
  • S3 1,310.27

What's your outlook on Emcure Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 7,256.12 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 12% is healthy, ROE of 21% is exceptional. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around -0% and 0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Supplies and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-13 Quarterly Results

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

78.08%
3.3%
0.49%
2.91%
5.01%
10.21%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,372 As on 21 December, 2024 | 18:41

The Market Cap of Emcure Pharmaceuticals is ₹26007.1 Cr As on 21 December, 2024 | 18:41

The P/E ratio of Emcure Pharmaceuticals is 45.8 As on 21 December, 2024 | 18:41

The PB ratio of Emcure Pharmaceuticals is 8.3 As on 21 December, 2024 | 18:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23